Literature DB >> 30145151

Treatment options and clinical outcomes for carbapenem-resistant Enterobacteriaceae bloodstream infection in a Chinese university hospital.

Chen Li1, Yi Li2, Zhichang Zhao3, Qing Liu4, Bin Li5.   

Abstract

BACKGROUND: Carbapenem resistant Enterobacteriaceae (CRE) has become a serious public health problem. Limited information is available about the treatment options that physicians used to fight CRE infections and related clinical outcomes in China. The aim of the present study was to explore the treatment options and clinical outcomes of patients with CRE bloodstream infection (BSI) in a Chinese teaching hospital.
METHODS: A retrospective study was conducted during 2011 to 2015 in one Chinese teaching hospital. Demographic, microbiological and clinical characteristics of enrolled subjects were collected from medical records. Data were analyzed by Kaplan-Meier graphs, log-rank test, and Cox regression.
RESULTS: A total of 98 inpatients with CRE BSI were enrolled in this study. For empirical therapy, 26 patients (26.5%) received at least one active drug within 48h after the onset of bacteremia. For definitive treatment, 59.2% (49/82) patients received at least one active drug and 40.2% (33/82) patients received therapy with no active drug. The overall 30-day mortality was 53.1% (52/98). Adverse outcome appeared to be more likely among patients with previous carbapenem exposure, neutropenia, severity of septic and time to initiation of BSIs. There was no significant difference in the mortality between the two groups of patients with combination therapy versus monotherapy (p=0.105). Severity of sepsis and neutropenia were identified as independent predictors of mortality.
CONCLUSIONS: Our study demonstrated a high mortality associated with CRE BSI and a high percentage of inappropriate empirical treatment for CRE BSI patients in a Chinese teaching hospital. Particular attention should be given to the patients with CRE BSI.
Copyright © 2018 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Antimicrobial therapy; Bloodstream infection; Carbapenem-resistant Enterobacteriaceae

Mesh:

Substances:

Year:  2018        PMID: 30145151     DOI: 10.1016/j.jiph.2018.08.002

Source DB:  PubMed          Journal:  J Infect Public Health        ISSN: 1876-0341            Impact factor:   3.718


  6 in total

1.  Socioeconomic Burden of Bloodstream Infections Caused by Carbapenem-Resistant Enterobacteriaceae.

Authors:  Yunying Zhu; Tingting Xiao; Yuan Wang; Kai Yang; Yanzi Zhou; Qixia Luo; Ping Shen; Yonghong Xiao
Journal:  Infect Drug Resist       Date:  2021-12-14       Impact factor: 4.003

2.  Predictors of Mortality in Patients with Carbapenem-Resistant Gram-Negative Bacilli or Vancomycin-Resistant Enterococci Bacteremia.

Authors:  Hye Jin Shi; Jin Seo Lee; Yong Kyun Cho; Joong Sik Eom
Journal:  Infect Drug Resist       Date:  2020-10-09       Impact factor: 4.003

Review 3.  It's Not Easy Being Green: A Narrative Review on the Microbiology, Virulence and Therapeutic Prospects of Multidrug-Resistant Pseudomonas aeruginosa.

Authors:  Payam Behzadi; Zoltán Baráth; Márió Gajdács
Journal:  Antibiotics (Basel)       Date:  2021-01-04

4.  Risk Factors for Mortality and Outcomes in Hematological Malignancy Patients with Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infections.

Authors:  Haiyang Meng; Lu Han; Mengxia Niu; Lu Xu; Min Xu; Qi An; Jingli Lu
Journal:  Infect Drug Resist       Date:  2022-08-04       Impact factor: 4.177

5.  Demographic, clinical, and outcome characteristics of carbapenem-resistant Enterobacteriaceae over a 10-year period (2010-2020) in Oman.

Authors:  Faryal Khamis; Ibrahim Al-Zakwani; Mariya Molai; Jalila Mohsin; Samta Al Dowaiki; Maher Al Bahrani; Eskild Petersen
Journal:  IJID Reg       Date:  2022-08-04

Review 6.  Epidemiological characteristics and molecular evolution mechanisms of carbapenem-resistant hypervirulent Klebsiella pneumoniae.

Authors:  Yu-Ling Han; Xu-Hui Wen; Wen Zhao; Xi-Shan Cao; Jian-Xun Wen; Jun-Rui Wang; Zhi-De Hu; Wen-Qi Zheng
Journal:  Front Microbiol       Date:  2022-09-12       Impact factor: 6.064

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.